Agenda Item No: 13

ockton Quarterly Performance Report to SSP 2010/11 (	ຊ1		David Hughes 1	7/09/10
PDUs in effective treatment (based on Glasgow preva	alence model)			
2009/10 end of year target: 1,291				
2009/10 end of year actual: 1,205				
Deficit: 86				
Revised 2010/11 target: 1,323 (require ne	et gain 118 PDUs)			
2 New treatment journeys into effective treatment	2009/10 Q4	Journeys 283	%<12 weeks <b>89%</b>	S
	2010/11 Q1	278	91%	
		Exits	% planned	
Planned discharges	2009/10 Q4 YTD 2010/11 Q1 YTD	200 92	33% 33%	
		aivon first i	ntervention w	ithin 2 wool
Waiting times (first treatment intervention)	2009/10 Q4	givennistn	95%	iumii 3 weer
	2010/11 Q1		95%	
	2009/10 Q4			/11 Q1
DIP referrals	Number % <b>32</b> -		Number 53	%
Clients not in treatment since 2004	4 13%		1	2%
Already in treatment at time of DIP referral	11 34%		13	25%
Clients triaged following referral	15 47%		36	68%
Of those triaged, clients started treatment	15 100%	I	36	100%
Harm Reduction and healthcare indicators (YTD)	2000/40 04		2010/11 Q1	
New presentations offered HBV vaccination New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC te			99% 20% 60% 98%	
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV	<b>98%</b> 47% / test 62%		<mark>99%</mark> 20% 60%	
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11)	98%           47%           62%           est         97%           8 Drug free treatme	nt exits	99% 20% 60% 98%	Q1 10/11
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment	98% 47% 62% est 97% 8 Drug free treatme Community	nt exits	99% 20% 60% 98% Q4 09/10 44	31
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14%	98%           47%           62%           est         97%           8 Drug free treatme	nt exits	99% 20% 60% 98%	
New presentations commencing HBV vaccinations         Percentage with injecting history who have received HCV         New presentations (with injecting history) offered HepC to         Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11)         Caseload       % accessing other treatment         Birchtree       713       14%         ABS       455       11%	98% 47% 62% est 97% 8 Drug free treatme Community	nt exits	99% 20% 60% 98% Q4 09/10 44 4	31 6
New presentations commencing HBV vaccinations         Percentage with injecting history who have received HCV         New presentations (with injecting history) offered HepC te         Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11)         Caseload       % accessing other treatment         Birchtree       713       14%         ABS       455       11%         Primary Crack/Cocaine users in Treatment YTD       Number of Primary Crack/Cocaine Users	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat	nt exits treatment ment becoming to Young Adu	99% 20% 60% 98% Q4 09/10 44 4 comorrow's F	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) <i>Caseload % accessing other treatment</i> Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to	nt exits r treatment ment becoming f Young Adu 18y/o	99% 20% 60% 98% Q4 09/10 44 4 somorrow's F ults in Treatm 19y/o	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to         01	nt exits treatment ment becoming f Young Adu 18y/o 11	99% 20% 60% 98% Q4 09/10 44 4 somorrow's F ults in Treatm 19y/o 6	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC te Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to         01	nt exits treatment ment becoming to Young Adu 18y/o 11 12	99% 20% 60% 98% Q4 09/10 44 4 somorrow's F ults in Treatm 19y/o	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	<ul> <li>98%</li> <li>47%</li> <li>62%</li> <li>97%</li> <li>8 Drug free treatme</li> <li>Community Tier 4 treat</li> <li>10 Reducing those to the set</li> <li>Q1</li> </ul>	nt exits treatment ment becoming f Young Adu 18y/o 11	99% 20% 60% 98% Q4 09/10 44 4 somorrow's F ults in Treatm 19y/o 6 6 6	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC te Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to         01 Q1         02 Q1         03 Q3         04 Q4	nt exits treatment ment becoming f Young Adu 18y/o 11 12 13	99% 20% 60% 98% Q4 09/10 44 4 3 comorrow's F ults in Treatm 19y/o 6 6 6 11	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC to Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to         01 Q1         02 Q1         03 Q3         04 Q4	nt exits treatment ment pecoming f Young Adu 18y/o 11 12 13 15	99% 20% 60% 98% Q4 09/10 44 4 3 comorrow's F ults in Treatm 19y/o 6 6 11 11 14	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC te Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	98%         47%         62%         97%         8 Drug free treatme         Community         Tier 4 treat         10 Reducing those to         0       Q1         10       Q2         0       Q1         10       Q2         0       Q1         10       Q2         0       Q3         0       Q1         10       Q2         0       Q3         0       Q1         10       Q2         0       Q3	nt exits treatment ment pecoming f Young Adu 18y/o 11 12 13 15	99% 20% 60% 98% Q4 09/10 44 4 3 comorrow's F ults in Treatm 19y/o 6 6 11 11 14	31 6 PDUs
New presentations commencing HBV vaccinations Percentage with injecting history who have received HCV New presentations (with injecting history) offered HepC te Percentage of ABS/Birchtree clients who are also accessing other structured treatment (Q1 2010/11) Caseload % accessing other treatment Birchtree 713 14% ABS 455 11% Primary Crack/Cocaine users in Treatment YTD Number of Primary Crack/Cocaine Users in Treatment YTD	$ \begin{array}{c}                                     $	nt exits treatment ment pecoming f Young Adu 18y/o 11 12 13 15	99% 20% 60% 98% Q4 09/10 44 4 3 comorrow's F ults in Treatm 19y/o 6 6 11 11 14	31 6 PDUs

